Investigation into Select Medical's Transaction Announced
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 hours ago
0mins
Should l Buy SEM?
Source: PRnewswire
- Shareholder Rights Investigation: Ademi LLP is investigating Select Medical for potential breaches of fiduciary duty in its transaction with a consortium led by Robert A. Ortenzio, with an enterprise value of approximately $3.9 billion, which may affect shareholder rights.
- Cash Acquisition Price: In this transaction, Select Medical shareholders will receive $16.50 per share in cash, a price that may not reflect the company's true value, potentially harming shareholder interests.
- Limitation on Competing Transactions: The transaction agreement imposes significant penalties for accepting competing bids, which could undermine shareholders' rights and potential returns.
- Board Conduct Review: We are examining the conduct of Select Medical's board to determine if they are fulfilling their fiduciary duties to all shareholders, ensuring that shareholder rights are protected.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SEM
Wall Street analysts forecast SEM stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.970
Low
17.00
Averages
18.75
High
21.00
Current: 14.970
Low
17.00
Averages
18.75
High
21.00
About SEM
Select Medical Holdings Corporation operates critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics in the United States. Its segments include Critical Illness Recovery Hospital, Rehabilitation Hospital, and Outpatient Rehabilitation. Critical Illness Recovery Hospital segment consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs. It operates the majority of its critical illness recovery hospitals as a hospital within a hospital (an HIH). Rehabilitation Hospital segment serves patients that require intensive physical rehabilitation care. Outpatient Rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services. It operates around 105 critical illness recovery hospitals in 29 states, 36 rehabilitation hospitals in 14 states, and 1,922 outpatient rehabilitation clinics in 39 states and the District of Columbia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SELECT MEDICAL HOLDINGS CORP: TRANSACTION VALUED AT $3.9 BILLION
Company Overview: Selected Medical Holdings Corp is involved in the healthcare sector, focusing on providing medical services and solutions.
Valuation Details: The company is currently representing an enterprise value of $3.9 billion, indicating its market worth and financial standing.
See More
Consortium to Acquire Select Medical Holdings Corp Shares at $16.50 Each
Acquisition Announcement: Selected Medical Holdings Corp. has announced its intention to acquire Select Medical shares.
Purchase Price: The shares are being offered at a price of $16.50 per share.
See More
Select Medical Announces $3.9 Billion Acquisition Agreement
- Acquisition Agreement: Select Medical Holdings announced a definitive agreement for a $3.9 billion acquisition led by executive chairman Robert A. Ortenzio, offering $16.50 per share in cash, representing an approximately 18% premium over the unaffected share price.
- Stock Price Surge: Following the announcement, Select Medical's shares rose over 7% in after-hours trading, reflecting a positive market reaction to the acquisition news and indicating investor confidence in future growth prospects.
- Future Revenue Outlook: Select Medical anticipates revenue of up to $5.8 billion in 2026, suggesting that the company's inpatient rehab expansion plans are advancing, which could further enhance its market share.
- Transaction Timeline: The merger is expected to close in mid-2026 and is not subject to a financing condition, indicating the robustness of the deal and the certainty of execution.
See More
Investigation into Select Medical Acquisition
- Acquisition Price Investigation: Halper Sadeh LLC is investigating the sale of Select Medical Holdings Corporation to a consortium led by executives for $16.50 per share, focusing on whether the best price for shareholders was obtained.
- Fair Sales Process: The investigation also examines whether Select Medical's board of directors ensured a fair sales process free from conflicts of interest, potentially harming shareholder interests.
- Disclosure Failures: Halper Sadeh highlights that Select Medical may have failed to disclose all material information, impacting shareholders' ability to evaluate the transaction and make informed decisions.
- Potential Legal Remedies: On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief measures to protect shareholders' rights and interests.
See More
Investigation into Select Medical's Transaction Announced
- Shareholder Rights Investigation: Ademi LLP is investigating Select Medical for potential breaches of fiduciary duty in its transaction with a consortium led by Robert A. Ortenzio, with an enterprise value of approximately $3.9 billion, which may affect shareholder rights.
- Cash Acquisition Price: In this transaction, Select Medical shareholders will receive $16.50 per share in cash, a price that may not reflect the company's true value, potentially harming shareholder interests.
- Limitation on Competing Transactions: The transaction agreement imposes significant penalties for accepting competing bids, which could undermine shareholders' rights and potential returns.
- Board Conduct Review: We are examining the conduct of Select Medical's board to determine if they are fulfilling their fiduciary duties to all shareholders, ensuring that shareholder rights are protected.
See More
Select Medical Enters Definitive Merger Agreement with Consortium
- Merger Agreement Reached: Select Medical Holdings Corporation announced a definitive merger agreement with a consortium led by Robert A. Ortenzio to acquire all outstanding shares not already owned by the consortium at $16.50 per share, representing a total transaction value of $3.9 billion, indicating strong confidence from the consortium in Select Medical's future.
- Shareholder Interests Protected: The merger agreement received unanimous approval from the disinterested members of Select Medical's Board, with the Special Committee determining that the transaction is fair and in the best interests of unaffiliated shareholders, ensuring protection of shareholder rights.
- Clear Transaction Conditions: The merger is expected to close in mid-2026, subject to customary conditions including shareholder voting and regulatory approvals, reflecting the consortium's confidence in the smooth execution of the transaction and highlighting their commitment to future business development.
- Management Stability: Post-merger, Select Medical will continue its operations with the current management team expected to remain in place, which will help maintain operational continuity and stability, further enhancing market trust.
See More
SELECT MEDICAL HOLDINGS CORP: TRANSACTION VALUED AT $3.9 BILLION
Company Overview: Selected Medical Holdings Corp is involved in the healthcare sector, focusing on providing medical services and solutions.
Valuation Details: The company is currently representing an enterprise value of $3.9 billion, indicating its market worth and financial standing.
See More
Consortium to Acquire Select Medical Holdings Corp Shares at $16.50 Each
Acquisition Announcement: Selected Medical Holdings Corp. has announced its intention to acquire Select Medical shares.
Purchase Price: The shares are being offered at a price of $16.50 per share.
See More
Select Medical Announces $3.9 Billion Acquisition Agreement
- Acquisition Agreement: Select Medical Holdings announced a definitive agreement for a $3.9 billion acquisition led by executive chairman Robert A. Ortenzio, offering $16.50 per share in cash, representing an approximately 18% premium over the unaffected share price.
- Stock Price Surge: Following the announcement, Select Medical's shares rose over 7% in after-hours trading, reflecting a positive market reaction to the acquisition news and indicating investor confidence in future growth prospects.
- Future Revenue Outlook: Select Medical anticipates revenue of up to $5.8 billion in 2026, suggesting that the company's inpatient rehab expansion plans are advancing, which could further enhance its market share.
- Transaction Timeline: The merger is expected to close in mid-2026 and is not subject to a financing condition, indicating the robustness of the deal and the certainty of execution.
See More
Investigation into Select Medical Acquisition
- Acquisition Price Investigation: Halper Sadeh LLC is investigating the sale of Select Medical Holdings Corporation to a consortium led by executives for $16.50 per share, focusing on whether the best price for shareholders was obtained.
- Fair Sales Process: The investigation also examines whether Select Medical's board of directors ensured a fair sales process free from conflicts of interest, potentially harming shareholder interests.
- Disclosure Failures: Halper Sadeh highlights that Select Medical may have failed to disclose all material information, impacting shareholders' ability to evaluate the transaction and make informed decisions.
- Potential Legal Remedies: On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief measures to protect shareholders' rights and interests.
See More
Investigation into Select Medical's Transaction Announced
- Shareholder Rights Investigation: Ademi LLP is investigating Select Medical for potential breaches of fiduciary duty in its transaction with a consortium led by Robert A. Ortenzio, with an enterprise value of approximately $3.9 billion, which may affect shareholder rights.
- Cash Acquisition Price: In this transaction, Select Medical shareholders will receive $16.50 per share in cash, a price that may not reflect the company's true value, potentially harming shareholder interests.
- Limitation on Competing Transactions: The transaction agreement imposes significant penalties for accepting competing bids, which could undermine shareholders' rights and potential returns.
- Board Conduct Review: We are examining the conduct of Select Medical's board to determine if they are fulfilling their fiduciary duties to all shareholders, ensuring that shareholder rights are protected.
See More
Select Medical Enters Definitive Merger Agreement with Consortium
- Merger Agreement Reached: Select Medical Holdings Corporation announced a definitive merger agreement with a consortium led by Robert A. Ortenzio to acquire all outstanding shares not already owned by the consortium at $16.50 per share, representing a total transaction value of $3.9 billion, indicating strong confidence from the consortium in Select Medical's future.
- Shareholder Interests Protected: The merger agreement received unanimous approval from the disinterested members of Select Medical's Board, with the Special Committee determining that the transaction is fair and in the best interests of unaffiliated shareholders, ensuring protection of shareholder rights.
- Clear Transaction Conditions: The merger is expected to close in mid-2026, subject to customary conditions including shareholder voting and regulatory approvals, reflecting the consortium's confidence in the smooth execution of the transaction and highlighting their commitment to future business development.
- Management Stability: Post-merger, Select Medical will continue its operations with the current management team expected to remain in place, which will help maintain operational continuity and stability, further enhancing market trust.
See More
